Corporate Profile
NovaBay is focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and community environments. Many of these infections have become increasingly difficult to treat because of the rapid increase in infectious microbes that have become resistant to current drugs. Our in vitro and in vivo tests have demonstrated that our compounds kill a wide range of bacteria, viruses and other infection causing microbes, including those that are resistant to multiple antibiotics. We are developing hospital indications ourselves and have partnered certain other indications with Alcon, the world's leading eye care company, and with Kinetic Concepts, Inc., (KCI), the leading company in advanced woundcare technology.
Press Releases
March 18, 2008
NovaBay Pharmaceuticals (NBY) Publishes on the Design of New Class of Antimicrobial Compounds It Named Aganocides™
March 11, 2008
NovaBay Pharmaceuticals (NBY) Reports Fourth Quarter and Year End 2007 Results –Provides Corporate Highlights
March 7, 2008
NovaBay Pharmaceuticals Commences Phase I Human Clinical Trial for the Prevention of Catheter Associated Urinary Tract Infections
March 4, 2008
NovaBay Pharmaceuticals, Inc. Announces Year End 2007 Earnings Conference Call
February 26, 2008
NovaBay Pharmaceuticals Presentation at the 20th Annual Roth Capital
OC Growth Stock Conference Featured on MSN Money
February 12, 2008
NovaBay Pharmaceuticals Receives Allowance of Patent Covering NeutroPhase™ Product
February 7, 2008
NovaBay Pharmaceuticals To Present At Two Upcoming Healthcare Conferences
February 5, 2008
NovaBay Informs Investors of Inaccuracies on Yahoo! Finance
January 28, 2008
NovaBay Pharmaceuticals Rang Opening Bell At The American Stock Exchange Friday, January 25, 2008
January 22, 2008
NovaBay Pharmaceutical’s Investigational New Drug Application (IND) for the Prevention of Catheter Associated Urinary Tract Infections Cleared by FDA
January 10, 2008
NovaBay Pharmaceuticals Appoints Thomas J. Paulson Chief Financial Officer
December 5, 2007
NovaBay Pharmaceuticals, Inc. to Present at the New York Society of
Security Analysts Biotech/Specialty Pharma Conference
November 26, 2007
Novabay Pharmaceuticals, Inc. Announces positive phase 1 study results with lead Aganocide compound
November 20, 2007
NovaBay Pharmaceuticals, Inc. Retains The Investor Relations Group of New York
NovaBay Pharmaceuticals, Inc. Featured In November/December Issue of PharmaVOICE
November 15, 2007
NovaBay Announces Third Quarter 2007 Financial Results
October 31, 2007
NovaBay Pharmaceuticals Closes Initial Public Offering of Common Stock